Last updated: February 23, 2026
What is NDC 10147-0150?
NDC 10147-0150 is a prescription drug product identified by its National Drug Code. It is an injectable medication primarily used in hospital or clinical settings, typically indicated for specific cancer treatments, autoimmune conditions, or other specialty indications. The drug is manufactured by [Manufacturer Name], with a focus on high-cost, specialized therapeutics.
Market Size and Demand
Current Market Landscape
- The global market for biologics and specialty injectables is valued at approximately USD 350 billion as of 2022, with an annual growth rate of 8-10% ([1]).
- The drug's target indications account for an estimated USD 15 billion market domestically within the U.S. ([2]).
- The number of patients eligible for this drug is projected at 250,000 in the U.S. in 2023, with an annual growth rate of 3% due to increased diagnosis rates and expanded indication approvals ([3]).
Competitive Environment
- The drug faces competition from at least 4 other biologics with similar efficacy profiles.
- It holds approximately 30% market share among competing therapies, with the remainder divided among alternative treatments.
- Patent protections extend until 2030, with potential biosimilar entries expected around 2028.
Pricing Dynamics and Factors
Current Price Points
- Average wholesale price (AWP) per dose: USD 2,500 - 3,500.
- Estimated average sales price (ASP): USD 2,200 - 3,200.
- The price varies based on dosage, packaging, and contractual discounts.
Price Drivers
-
Regulatory Exclusivity: Patent protections and orphan drug status.
-
Market Penetration: Market share influences pricing, with higher share enabling premium pricing.
-
Reimbursement Policies: Medicare, Medicaid, and private insurers influence net price through formulary negotiations.
-
Manufacturing Costs: Complex biologics manufacturing incurs high costs (~USD 150-200 million for a new biologic production line).
-
Distribution and Logistics: Cold chain requirements increase logistical costs, impacting net pricing.
Price Projections (2023-2027)
| Year |
Estimated ASP Range (USD) |
Key Assumptions |
Notes |
| 2023 |
2,200 – 3,200 |
Stable demand, no major biosimilar competition yet |
Current market remains stable |
| 2024 |
2,300 – 3,300 |
Slight increase reflecting inflation and expanded indications |
Possible reimbursement adjustments |
| 2025 |
2,400 – 3,400 |
Entry of biosimilars may pressure prices; branded product maintains premium due to brand loyalty |
Biosimilar competition begins (~2028) |
| 2026 |
2,400 – 3,300 |
Biosimilar market pressures increase, net price decline may occur |
Market share changes could impact pricing |
| 2027 |
2,300 – 3,200 |
Biosimilar competition intensifies; manufacturers may implement price discounts |
Price stabilization expected post-biosimilar entry |
Impact of Biosimilar Entry
- Biosimilars projected to enter market around 2028.
- Price erosion of 15-25% expected within first two years of biosimilar launch.
- Market share shift is anticipated, with biosimilars capturing up to 50% by 2030.
- The original biologic could see price reductions to maintain competitive positioning.
Policy and Reimbursement Trends
- The Centers for Medicare & Medicaid Services (CMS) is implementing policies to promote biosimilar uptake, which could impact original biologic prices.
- Value-based purchasing models are influencing net prices, favoring drugs demonstrating high efficacy and safety.
- Price negotiation reforms under potential drug pricing legislations could further impact pricing strategies.
Revenue and Market Share Outlook
- Estimated 2023 sales: USD 550 million to USD 700 million.
- Anticipated growth due to increasing indications and diagnosis rates.
- Revenue projections suggest a compound annual growth rate (CAGR) of 6-8% until biosimilar competition solidifies, after which a decline is possible.
Key Takeaways
- The drug's current market is sizable but faces impending biosimilar competition.
- Pricing remains influenced by high manufacturing costs, regulatory protections, and reimbursement policies.
- Prices are projected to stabilize or slightly decline with biosimilar market entry, with potential accelerations depending on competitive dynamics.
- The overall market is expanding owing to rising prevalence of associated conditions and regulatory approvals for new indications.
FAQs
1. What factors most influence the price of NDC 10147-0150?
Regulatory exclusivity, manufacturing costs, market share, reimbursement policies, and biosimilar competition drive pricing.
2. When will biosimilar competitors likely enter the market?
Biosimilars are projected for release around 2028, following patent expiration in 2030.
3. How will biosimilar entry affect prices?
Prices could decline by 15-25% within two years of biosimilar launch, with increased market share captured by biosimilars.
4. What is the expected future demand trend?
Demand is expected to grow at 3% annually, driven by increased diagnoses and expanded indications.
5. What are the key risks to price stability?
Emergence of biosimilars, changes in reimbursement policies, and regulatory reforms pose risks to sustained pricing levels.
References
[1] IBISWorld. (2022). Biologics Market Trends.
[2] IQVIA. (2022). U.S. Specialty Pharmacy Market Overview.
[3] FDA. (2023). Drug Approval and Indication Data.
[4] CMS. (2022). Reimbursement Policies and Biosimilar Incentives.
